Effect of different treatment modalities on ovarian cancer patients with liver metastases: A retrospective cohort study based on SEER

Author:

Li Na,Jin Shanxiu,Wu Jingran,Ji Hongjuan,Du Cheng,Liu BonaORCID

Abstract

Background To examine the trends in morbidity and mortality among ovarian cancer patients with liver metastases, and investigate the impact of different treatments on both overall survival (OS) and cancer-specific survival (CSS). Methods 2,925 ovarian cancer patients with liver metastases from Surveillance, Epidemiology, and End Results 2010–2019 were included. The primary endpoint was considered as OS and CSS. We conducted trend analysis of the incidence, OS and CSS rates of liver metastases in ovarian cancer. Univariate and multivariate COX proportional risk models were used to investigate the association between different treatment methods and OS, and univariate and multivariate competing risk models were employed to evaluate the impact of treatment methods on CSS. Results At the end of follow-up, 689 patients remained alive. The OS and CSS rates were 76.44% and 72.99% for all patients, respectively. There was a significant decreasing trend in the incidence [average annual percent change (AAPC) = -2.3, 95% confidence interval (CI): -3.9, -0.7], all-cause mortality (AAPC = -12.8, 95% CI: -15.6, -9.9) and specific mortality (AAPC = -13.0, 95% CI: -16.1, -9.8) rate of liver metastases in ovarian cancer. After adjusting all confounding factor, only receiving surgery was associated with OS [hazard ratio (HR) = 0.39, 95%CI: 0.31–0.48]/CSS (HR = 0.37, 95%CI: 0.30–0.47). Chemotherapy was found to be protective factor for OS (HR = 0.33, 95%CI: 0.30–0.37)/CSS (HR = 0.44, 95%CI: 0.39–0.50) of ovarian cancer patients, while not receiving surgery remained a risk factor. Additionally, the result of subgroup analyses also showed that only receiving surgery and chemotherapy still were significant protective factor of OS and CSS for patients without other distant metastases, with distant metastases to the bone, lung, brain or other organs, with bone metastasis, and with lung metastasis. Conclusion Our research has elucidated a downward trend in morbidity and mortality rates among patients with liver metastases originating from ovarian cancer. Only receiving surgery and chemotherapy as therapies methods confer survival benefits to patients.

Funder

Jilin Provincial Science and Technology Department Fund

Liaoning Provincial Science and Technology Talents and Natural Science Foundation

Jilin Provincial Department of Education Fund

Publisher

Public Library of Science (PLoS)

Reference24 articles.

1. NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.;DK Armstrong;J Natl Compr Canc Netw.,2022

2. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Ovarian Cancer. National Cancer Institute. https://seer.cancer.gov/statfacts/html/ovary.html.

3. A Population-Based Study on Liver Metastases in Women With Newly Diagnosed Ovarian Cancer.;H Zhao;Front Oncol,2020

4. Ovarian, uterine, and cervical cancer patients with distant metastases at diagnosis: most common locations and outcomes;AB Gardner;Clin Exp Metastasis,2020

5. Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients;K Deng;Gynecol Oncol,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3